Nordic Group and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company have partnered up to make Ozalin available in France.
Ozalin is an oral solution for children older than 6 months, which has been approved in several markets in the EU including France, to improve the palatability and acceptability for children.
Alan Knox, Primex’s Group CEO, said: “The partnership with Nordic Group represents an important achievement for Primex Pharmaceuticals and underscores our commitment to making Ozalin available across all EU member states. We are confident that Nordic Group with their experience in the hospital sector, will further support their portfolio in Anaesthesia in France.”
Vincent Leonhardt, Managing Director of Nordic Pharma in France said: “Nordic Pharma is delighted to have the opportunity to commercialize Ozalin, a product initially developed at Amiens hospital in France, and that will make a fundamental difference to children and their acceptability toward treatment.”